Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.

Villeneuve D, Brothers A, Harvey E, Kemna M, Law Y, Nemeth T, Gantt S.

Pediatr Transplant. 2013 Feb;17(1):80-5. doi: 10.1111/petr.12030. Epub 2012 Dec 13.

PMID:
23240598
[PubMed - indexed for MEDLINE]
2.

Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.

Pescovitz MD, Ettenger RB, Strife CF, Sherbotie JR, Thomas SE, McDiarmid S, Bartosh S, Ives J, Bouw MR, Bucuvalas J.

Transpl Infect Dis. 2010 Jun;12(3):195-203. doi: 10.1111/j.1399-3062.2009.00478.x. Epub 2009 Dec 4.

PMID:
20002356
[PubMed - indexed for MEDLINE]
3.

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.

Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N; Valganciclovir Solid Organ Transplant Study Group.

Clin Pharmacokinet. 2005;44(5):495-507.

PMID:
15871635
[PubMed - indexed for MEDLINE]
4.

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.

Åsberg A, Bjerre A, Neely M.

Pediatr Transplant. 2014 Feb;18(1):103-11. doi: 10.1111/petr.12179. Epub 2013 Oct 23.

PMID:
24152053
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.

Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP; Valganciclovir Solid Organ Transplant Study Group.

Transplantation. 2005 Jun 15;79(11):1477-83.

PMID:
15940035
[PubMed - indexed for MEDLINE]
6.

Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.

Vaudry W, Ettenger R, Jara P, Varela-Fascinetto G, Bouw MR, Ives J, Walker R; Valcyte WV16726 Study Group.

Am J Transplant. 2009 Mar;9(3):636-43. doi: 10.1111/j.1600-6143.2008.02528.x.

PMID:
19260840
[PubMed - indexed for MEDLINE]
Free Article
7.

The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.

Lapidus-Krol E, Shapiro R, Amir J, Davidovits M, Steinberg R, Mor E, Avitzur Y.

Pediatr Transplant. 2010 Sep 1;14(6):753-60. doi: 10.1111/j.1399-3046.2010.01330.x. Epub 2010 May 3.

PMID:
20477976
[PubMed - indexed for MEDLINE]
8.

Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.

Pescovitz MD, Brook B, Jindal RM, Leapman SB, Milgrom ML, Filo RS.

Clin Transplant. 1997 Dec;11(6):613-7.

PMID:
9408695
[PubMed - indexed for MEDLINE]
9.

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

Yu MA, Park JM.

Expert Opin Pharmacother. 2013 Apr;14(6):807-15. doi: 10.1517/14656566.2013.778244. Epub 2013 Mar 8. Review.

PMID:
23469871
[PubMed - indexed for MEDLINE]
10.

Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T.

Clin Pharmacokinet. 2009;48(6):399-418. doi: 10.2165/00003088-200948060-00006. Review.

PMID:
19650679
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group.

Am J Transplant. 2004 Apr;4(4):611-20.

PMID:
15023154
[PubMed - indexed for MEDLINE]
Free Article
12.

Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients.

Zhao W, Fakhoury M, Fila M, Baudouin V, Deschênes G, Jacqz-Aigrain E.

Ther Drug Monit. 2012 Jun;34(3):326-30. doi: 10.1097/FTD.0b013e3182509e3a.

PMID:
22495424
[PubMed - indexed for MEDLINE]
13.

Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.

Caldés A, Gil-Vernet S, Armendariz Y, Colom H, Pou L, Niubó J, Lladó L, Torras J, Manito N, Rufí G, Grinyó JM.

Transpl Infect Dis. 2010 Jun;12(3):204-12. doi: 10.1111/j.1399-3062.2009.00481.x. Epub 2009 Dec 9.

PMID:
20002612
[PubMed - indexed for MEDLINE]
14.

Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.

Cochrane AB.

Am J Health Syst Pharm. 2006 Oct 1;63(19 Suppl 5):S17-21. Review.

PMID:
16990640
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetic profile of valganciclovir in pediatric transplant recipients.

Launay E, Théôret Y, Litalien C, Duval M, Alvarez F, Lapeyraque AL, Phan V, Larocque D, Poirier N, Lamarre V, Ovetchkine P.

Pediatr Infect Dis J. 2012 Apr;31(4):405-7. doi: 10.1097/INF.0b013e3182463a19.

PMID:
22198827
[PubMed - indexed for MEDLINE]
16.

Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.

Oppenheimer F, Gonzalez-Molina M, Rubio M.

Clin Transplant. 2007 Jul-Aug;21(4):441-8.

PMID:
17645702
[PubMed - indexed for MEDLINE]
17.

Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.

Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC.

Antivir Ther. 2005;10(1):119-23.

PMID:
15751769
[PubMed - indexed for MEDLINE]
18.

Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.

Kiser TH, Fish DN, Zamora MR.

J Heart Lung Transplant. 2012 Feb;31(2):159-66. doi: 10.1016/j.healun.2011.11.016.

PMID:
22305377
[PubMed - indexed for MEDLINE]
19.

Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.

Pescovitz MD, Pruett TL, Gonwa T, Brook B, McGory R, Wicker K, Griffy K, Robinson CA, Jung D.

Transplantation. 1998 Oct 27;66(8):1104-7.

PMID:
9808499
[PubMed - indexed for MEDLINE]
20.

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.

Perrottet N, Manuel O, Lamoth F, Venetz JP, Sahli R, Decosterd LA, Buclin T, Pascual M, Meylan P.

BMC Infect Dis. 2010 Jan 6;10:2. doi: 10.1186/1471-2334-10-2.

PMID:
20053269
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk